{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:07:48Z","timestamp":1792789668667,"version":"4.5.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Before November 2023, CD19 chimeric antigen receptor (CAR) T-cell therapies had not been approved in China for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL), leaving a significant unmet need. In response, inaticabtagene autoleucel (Inati-cel), a novel CD19 CAR T-cell therapy with a distinct single-chain variable fragment (HI19\u03b1), was developed and showed promising efficacy in preliminary clinical research. We conducted a phase 2, single-arm, multicenter study of Inati-cel in adult CD19+ R\/R B-ALL in China. The primary end point was the overall remission rate (ORR) at the end of month 3. Forty-eight patients who underwent Inati-cel infusion were evaluated for both efficacy and safety. Among them, 34 patients achieved and maintained remission beyond 3\u00a0months, with a 3-month ORR of 70.8% (95% confidence interval [CI], 55.9-83.1). The best ORR was 85.4%, with all responders reaching minimal residual disease negativity. With a median follow-up of 23.7\u00a0months, the median duration of remission was 20.7\u00a0months (95%\u00a0CI, 6.4 to not reached), and the median overall survival was not reached (95%\u00a0CI, 13.0\u00a0months to not reached). Additionally, grade \u22653 cytokine release syndrome and neurologic events occurred in 12.5% and 6.2% of patients, respectively. The 2-year follow-up data suggest that Inati-cel demonstrates encouraging and durable responses with manageable safety profiles in R\/R B-ALL. Based on the data from this pivotal trial, Inati-cel was approved as the first CAR T-cell therapy for adult R\/R B-ALL in China and underscores its potential therapeutic benefits for this patient population. This trial was registered at www.ClinicalTrials.gov as #NCT04684147.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014182","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T17:31:56Z","timestamp":1733247116000},"page":"836-843","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-8064","authenticated-orcid":false,"given":"Ying","family":"Wang","sequence":"first","affiliation":[{"name":"1Leukemia Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center of Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Lv","sequence":"additional","affiliation":[{"name":"2Juventas Cell Therapy Ltd, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[{"name":"3Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Wei","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4015-3952","authenticated-orcid":false,"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1375-1084","authenticated-orcid":false,"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[{"name":"6Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Yan","sequence":"additional","affiliation":[{"name":"6Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"7Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma and Chemical Poisoning, Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyou","family":"Liu","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Beijing Gobroad Boren Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"9Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-1014","authenticated-orcid":false,"given":"Ting","family":"Niu","sequence":"additional","affiliation":[{"name":"11Department of Hematology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8607-207X","authenticated-orcid":false,"given":"Runxia","family":"Gu","sequence":"additional","affiliation":[{"name":"1Leukemia Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center of Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jienan","family":"Ren","sequence":"additional","affiliation":[{"name":"2Juventas Cell Therapy Ltd, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Feng","sequence":"additional","affiliation":[{"name":"2Juventas Cell Therapy Ltd, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jin","sequence":"additional","affiliation":[{"name":"2Juventas Cell Therapy Ltd, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[{"name":"2Juventas Cell Therapy Ltd, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Deng","sequence":"additional","affiliation":[{"name":"2Juventas Cell Therapy Ltd, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-9151","authenticated-orcid":false,"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"1Leukemia Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center of Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"5","key":"2025032418273282400_bib1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"2025032418273282400_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10299","key":"2025032418273282400_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"2025032418273282400_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025032418273282400_bib5","doi-asserted-by":"crossref","first-page":"23024","DOI":"10.1038\/s41598-023-48528-0","article-title":"Solving the mystery of the FMC63-CD19 affinity","volume":"13","author":"Seigner","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"2025032418273282400_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13045-020-00953-8","article-title":"Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia","volume":"13","author":"Gu","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"9","key":"2025032418273282400_bib7","doi-asserted-by":"crossref","first-page":"10638","DOI":"10.18632\/oncotarget.7079","article-title":"Construction of a new antiCD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells","volume":"7","author":"An","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"2025032418273282400_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2025032418273282400_bib9","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/ajh.26324","article-title":"The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: a 10-year retrospective study","volume":"96","author":"Zhou","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"2025032418273282400_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11912-012-0247-7","article-title":"Philadelphia-positive acute lymphoblastic leukemia: current treatment options","volume":"14","author":"Liu-Dumlao","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"2025032418273282400_bib11","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/leu.2010.177","article-title":"Genomic profiling of high-risk acute lymphoblastic leukemia","volume":"24","author":"Collins-Underwood","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"2025032418273282400_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"2025032418273282400_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"2025032418273282400_bib14","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","article-title":"Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies","volume":"43","author":"Totzeck","year":"2022","journal-title":"Eur Heart J"},{"key":"2025032418273282400_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"2025032418273282400_bib16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and safety of CD28- or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol Ther Oncolytics"},{"issue":"6","key":"2025032418273282400_bib17","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"2025032418273282400_bib18","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/bloodadvances.2022007057","article-title":"Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma","volume":"6","author":"Cuffel","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2025032418273282400_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jcyt.2013.10.013","article-title":"Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy","volume":"16","author":"Barrett","year":"2014","journal-title":"Cytotherapy"},{"issue":"27","key":"2025032418273282400_bib20","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2025032418273282400_bib21","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1038\/cti.2014.31","article-title":"Ex\u00a0vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS immune cell serum replacement","volume":"4","author":"Smith","year":"2015","journal-title":"Clin Transl Immunology"},{"issue":"21","key":"2025032418273282400_bib22","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/836\/2355950\/blooda_adv-2024-014182-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/836\/2355950\/blooda_adv-2024-014182-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T16:35:49Z","timestamp":1742834149000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/4\/836\/534301\/Inaticabtagene-autoleucel-in-adult-relapsed-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014182","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}